ZIDOVUDINE

Post-LOE

zidovudine

Aurobindo Pharma

ANDAORALSOLUTION

Approved

Sep 2005

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

ZIDOVUDINE (zidovudine) by Aurobindo Pharma is nucleoside reverse transcriptase inhibitors [moa]. Approved for maternal-fetal hiv-1 transmission [see ], combination with other antiretroviral agents for the treatment of hiv-1 infection. First approved in 2005.

Drug data last refreshed 19h ago

Mechanism of Action

Nucleoside Reverse Transcriptase Inhibitors

Pharmacologic Class:

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Indications (1)

combination with other antiretroviral agents for the treatment of HIV-1 infection

Clinical Trials (20)

NCT00002013N/ACompleted

A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC Patients

HIV Infections

NCT00002256N/ACompleted

Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine ( AZT ) Therapy.

HIV Infections

NCT00000791Phase 2Completed

A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV

210 enrolled

HIV Infections

NCT00000986Phase 1Completed

The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related Complex

18 enrolled

HIV Infections

NCT00001106Phase 1Completed

A Study of Zidovudine in HIV-Infected Pregnant Women and Their Children

40 enrolled

HIV InfectionsPregnancy

Worked on ZIDOVUDINE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.